Viridian Therapeutics CFO Kristian Humer resigns; Seth Harmon appointed principal financial officer

Viridian Therapeutics, Inc.\DE

Kristian Humer, CFO and CBO, resigns effective Sept 12, 2023; eligible for severance under existing agreement.
Seth Harmon, SVP of Finance (joined May 2023), assumes role of principal financial and accounting officer.
Harmon's base salary increased to $410,000; entitled to 12-month severance upon involuntary termination.
Harmon previously CFO of BioNTech US subsidiary and held finance roles at Neon Therapeutics and Merrimack.
Harmon is a CPA with prior experience at Ernst & Young.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kristian Humer

Chief Financial Officer and Chief Business Officer

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2023-09-12
Successor: Seth Harmon
Filed: September 12, 2023, 7:59 PM ET

On September 8, 2023, Kristian Humer, the Chief Financial Officer and Chief Business Officer of Viridian Therapeutics, Inc. (the “Company”), resigned, effective September 12, 2023.

Appointed

Seth Harmon

principal financial and accounting officer

VRDN · Viridian Therapeutics, Inc.\DE

Effective: 2023-09-12
Filed: September 12, 2023, 7:59 PM ET

on September 12, 2023, Seth Harmon, the Company’s Senior Vice President of Finance, assumed the role of the Company’s principal financial and accounting officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kristian Humer resigned as Chief Financial Officer and Chief Business Officer at Viridian Therapeutics, Inc.\DE.

Action: resigned
Role: Chief Financial Officer and Chief Business Officer

Exact text from the filing

On September 8, 2023, Kristian Humer, the Chief Financial Officer and Chief Business Officer of Viridian Therapeutics, Inc. (the “Company”), resigned, effective September 12, 2023.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Seth Harmon changed role as principal financial and accounting officer at Viridian Therapeutics, Inc.\DE.

Action: assumed the role
Role: principal financial and accounting officer

Exact text from the filing

on September 12, 2023, Seth Harmon, the Company’s Senior Vice President of Finance, assumed the role of the Company’s principal financial and accounting officer.

View on SEC.gov

Viridian Therapeutics, Inc.\DE filing history →

Source: SEC EDGAR

accession 0001193125-23-233500

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.